Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report report published on Thursday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Up 2.2 %

Shares of NYSE ENZ opened at $0.74 on Thursday. Enzo Biochem has a 12 month low of $0.68 and a 12 month high of $1.44. The business’s 50 day moving average is $0.97 and its two-hundred day moving average is $1.07.

Enzo Biochem (NYSE:ENZ) last announced its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Enzo Biochem Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were given a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 54.35%. The ex-dividend date of this dividend was Friday, November 15th.

Hedge Funds Weigh In On Enzo Biochem

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the period. BBR Partners LLC bought a new position in Enzo Biochem in the third quarter worth $112,000. XTX Topco Ltd boosted its stake in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares during the period. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.